Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Polychronis

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Transcription Factor FOXO3a Is a Crucial Cellular Target of Gefitinib (Iressa) in Breast Cancer Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Related publications

Updated Efficacy of Avelumab in Patients With Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-Up: JAVELIN Merkel 200, a Phase 2 Clinical Trial

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

KEYNOTE-045: Randomized Phase 3 Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Metastatic Urothelial Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Gefitinib Versus Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc): A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Atezolizumab in Japanese Patients With Previously Treated, Advanced Non–small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy